Product Description
XmAb942 is a monospecific anti-TL1A antibody, utilizing Xencor’s Xtend™ Fc Domain and proprietary Fc silencing technology, with potentially class-leading potency, and is under development for patients with inflammatory bowel diseases (IBD). The two most common forms of IBD are Crohn’s disease and ulcerative colitis. (Sourced from: https://xencor.com/pipeline/xmab942/)
Mechanisms of Action: TL1A Inhibitor,IL23 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GALE Therapeutics Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Inflammatory Bowel Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|